Circulation Cardiovascular Interventions · 2015 · 242 citations · 20 references
MedicineCardiologyPharmacotherapyBiocompatibilityBiomaterialsInterventional CardiologyAcute Coronary Syndrome InterventionAntiplatelet TherapyCoronary Artery DiseasePercutaneous Coronary InterventionPolymeric BiomaterialsThrombosis PreventionAntiplatelet Therapy After Percutaneous Coronary InterventionBioabsorbable PolymersClinical Safety EvaluationClinical Trial Safety AnalysisCoronary StentingEndothelializationPercutaneous Coronary Intervention CareStable Coronary Artery Disease Intervention
BACKGROUND: Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer. We performed a multicenter, randomized controlled trial for regulatory approval to determine noninferiority of the SYNERGY stent to the durable polymer PROMUS Element Plus everolimus-eluting stent. METHODS AND RESULTS: Patients (n=1684) scheduled to undergo percutaneous coronary intervention for non-ST-segment-elevation acute coronary syndrome or stable coronary artery disease were randomized to receive either the SYNERGY stent or the PROMUS Element Plus stent. The primary end point of 12-month target lesion failure was observed in 6.7% of SYNERGY and 6.5% PROMUS Element Plus treated subjects by intention-to-treat (P=0.83 for difference; P=0.0005 for noninferiority), and 6.4% in both the groups by per-protocol analysis (P=0.0003 for noninferiority). Clinically indicated revascularization of the target lesion or definite/probable stent thrombosis were observed in 2.6% versus 1.7% (P=0.21) and 0.4% versus 0.6% (P=0.50) of SYNERGY versus PROMUS Element Plus-treated subjects, respectively. CONCLUSIONS: In this randomized trial, the SYNERGY bioabsorbable polymer everolimus-eluting stent was noninferior to the PROMUS Element Plus everolimus-eluting stent with respect to 1-year target lesion failure. These data support the relative safety and efficacy of SYNERGY in a broad range of patients undergoing percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01665053.
20
Clinical End Points in Coronary Stent Trials
Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine, Eric Bates, James C. Blankenship et al. · Circulation · 2011 · 3.3K citations · Full text
Medicine, Cardiology, Surgery +14
Pathology of Drug-Eluting Stents in Humans
Michael Joner, Aloke V. Finn, Andrew Farb et al. · Journal of the American College of Cardiology · 2006 · 2.7K citations
Medicine, Cardiology, Pathology +11
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine, Eric Bates, James C. Blankenship et al. · Journal of the American College of Cardiology · 2011 · 2.2K citations
Medicine, Cardiology, Surgery +14
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Laura Mauri, Robert W. Yeh, Priscilla Driscoll-Shempp et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text